epilepsiaEpilepsy and paroxysmal conditionsЭпилепсия и пароксизмальные состояния2077-83332311-4088IRBIS LLC10.17749/2077-8333/epi.par.con.2026.258epilepsia-1313Research ArticleSCIENTIFIC SURVEYSНАУЧНЫЕ ОБЗОРЫRare levetiracetam-related adverse events in treatment of epilepsyРедкие нежелательные реакции на леветирацетам при лечении эпилепсииhttps://orcid.org/0000-0001-6693-8710МелашенкоТ. В.MelashenkoT. V.

Мелашенко Татьяна Владимировна - к.м.н.

Заводской пр-т, д. 1, Колпино, Санкт-Петербург 196657

Tatiana V. Melashenko - PhD.

1 Zavodskoy Ave., Kolpino, Saint Petersburg 196657

https://orcid.org/0000-0002-5809-1457ТадтаеваЗ. Г.TadtaevaZ. G.

Тадтаева Зара Григорьевна - д.м.н., проф.

ул. Литовская, д. 2, Санкт-Петербург 194100

Zara G. Tadtaeva - Dr. Sci. Med., Prof.

2 Litovskaya Str., Saint Petersburg 194100

https://orcid.org/0000-0001-9679-632XГалустянА. Н.GalustyanA. N.

Галустян Анна Николаевна - к.м.н., доцент.

ул. Литовская, д. 2, Санкт-Петербург 194100

Anna N. Galustyan - PhD, Assoc. Prof.

2 Litovskaya Str., Saint Petersburg 194100

https://orcid.org/0009-0002-8422-5487ГаланкинН. A.GalankinN. A.

Галанкин Никита Александрович.

ул. Литовская, д. 2, Санкт-Петербург 194100; ул. Академика Павлова, д. 12, Санкт-Петербург 197022

WoS ResearcherID KDP-1487-2024, Scopus Author ID 59906453700

Nikita A. Galankin.

2 Litovskaya Str., Saint Petersburg 194100; 12 Academician Pavlov Str., Saint Petersburg 197022

WoS ResearcherID KDP-1487-2024, Scopus Author ID 59906453700

galankinn1999@gmail.comhttps://orcid.org/0000-0002-7663-710XГромоваО. А.GromovaO. A.

Громова Ольга Алексеевна - д.м.н., проф.

ул. Вавилова, д. 44, корп. 2, Москва 119333

WoS ResearcherID J-4946-2017, Scopus Author ID 7003589812

Olga A. Gromova - Dr. Sci. Med., Prof.

44 corp. 2 Vavilov Str., Moscow 119333

WoS ResearcherID J-4946-2017, Scopus Author ID 7003589812

https://orcid.org/0000-0002-1528-411XСардарянИ. С.SardaryanI. S.

Сардарян Иван Суренович - к.м.н., доцент.

ул. Литовская, д. 2, Санкт-Петербург 194100

Scopus Author ID 57200672112

Ivan S. Sardaryan - PhD, Assoc. Prof.

2 Litovskaya Str., Saint Petersburg 194100

Scopus Author ID 57200672112

Санкт-Петербургское государственное бюджетное учреждение здравоохранения «Детская городская больница № 22»РоссияChildren's Clinical Hospital No. 22Russian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский педиатрический медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияSaint Petersburg Pediatric Medical UniversityRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский педиатрический медицинский университет» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное научное учреждение «Институт экспериментальной медицины»РоссияSaint Petersburg Pediatric Medical University; Institute of Experimental MedicineRussian FederationФедеральный исследовательский центр «Информатика и управление» Российской академии наукРоссияFederal Research Center “Computer Science and Control”, Russian Academy of SciencesRussian Federation2026250420261813847Copyright © Melashenko T.V., Tadtaeva Z.G., Galustyan A.N., Galankin N.A., Gromova O.A., Sardaryan I.S., 20262026Мелашенко Т.В., Тадтаева З.Г., Галустян А.Н., Галанкин Н.A., Громова О.А., Сардарян И.С.Melashenko T.V., Tadtaeva Z.G., Galustyan A.N., Galankin N.A., Gromova O.A., Sardaryan I.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epilepsia.su/jour/article/view/1313

The article systematizes data on rare levetiracetam-related adverse events that go beyond the approved data provided in package insert. The key factor in selecting an antiepileptic drug is the risk-benefit ratio, which is largely determined by the knowledge of all potential adverse effects. This review aims to increase awareness of adverse reactions to levetiracetam in patients with epilepsy. Further research is needed to explore the pathogenetic mechanisms and identify risk factors of adverse effects for better understanding of the drug safety profile.

В работе систематизированы данные о редких нежелательных реакциях на леветирацетам, выходящих за рамки общепринятых сведений, изложенных в инструкции по применению. Ключевым при подборе антиэпилептического препарата является соотношение «польза/риск», которое во многом определяется осведомленностью обо всех возможных побочных действиях. Проведенный обзор литературы призван повысить уровень информированности о нежелательных реакциях на леветирацетам у пациентов с эпилепсией. Для углубленного понимания профиля безопасности препарата необходимы дальнейшие исследования, направленные на изучение патогенетических механизмов побочных действий и идентификацию факторов риска их развития.

леветирацетамэпилепсияантиэпилептический препаратнежелательные реакциибезопасностьфармакокинетикапереносимостьlevetiracetamepilepsyantiepileptic drugadverse reactionssafetypharmacokineticstolerabilityReferencesClavenna A., Bonati M. Adverse drug reactions in childhood: a review of prospective studies and safety alerts. Arch Dis Child. 2009; 94 (9): 724–8. https://doi.org/10.1136/adc.2008.154377.Clavenna A., Bonati M. Adverse drug reactions in childhood: a review of prospective studies and safety alerts. Arch Dis Child. 2009; 94 (9): 724–8. https://doi.org/10.1136/adc.2008.154377.Perucca P., Carter J., Vahle V., Gilliam F.G. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology. 2009; 72 (14): 1223–9. https://doi.org/10.1212/01.wnl.0000345667.45642.61.Perucca P., Carter J., Vahle V., Gilliam F.G. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology. 2009; 72 (14): 1223–9. https://doi.org/10.1212/01.wnl.0000345667.45642.61.Giussani G., Bianchi E., Canelli V., et al. Antiepileptic drug discontinuation by people with epilepsy in the general population. Epilepsia. 2017; 58 (9): 1524–32. https://doi.org/10.1111/epi.13853.Giussani G., Bianchi E., Canelli V., et al. Antiepileptic drug discontinuation by people with epilepsy in the general population. Epilepsia. 2017; 58 (9): 1524–32. https://doi.org/10.1111/epi.13853.Perucca P., Gilliam F.G. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012; 11 (9): 792–802. https://doi.org/10.1016/S1474-4422(12)70153-9.Perucca P., Gilliam F.G. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012; 11 (9): 792–802. https://doi.org/10.1016/S1474-4422(12)70153-9.Тадтаева З.Г., Галустян А.Н., Громова О.А. и др. Фармакотерапия эпилепсии: краткий справочник. М.: ГЭОТАР-Медиа; 2023: 94 с.Tadtaeva Z.G., Galustyan A.N., Gromova O.A., et al. Pharmacotherapy of epilepsy: a brief reference guide. Moscow: GEOTAR-Media; 2023: 94 pp. (in Russ.).Egunsola O., Choonara I., Sammons H.M. Safety of levetiracetam in paediatrics: a systematic review. PLoS One. 2016; 11 (3): e0149686. https://doi.org/10.1371/journal.pone.0149686.Egunsola O., Choonara I., Sammons H.M. Safety of levetiracetam in paediatrics: a systematic review. PLoS One. 2016; 11 (3): e0149686. https://doi.org/10.1371/journal.pone.0149686.de Toledo M., de la Fuente E., Ramos C., et al. Extensive pharmacokinetic variability of levetiracetam. Are doctors aware? Epilepsy Res. 2022; 187: 107029. https://doi.org/10.1016/j.eplepsyres.2022.107029.de Toledo M., de la Fuente E., Ramos C., et al. Extensive pharmacokinetic variability of levetiracetam. Are doctors aware? Epilepsy Res. 2022; 187: 107029. https://doi.org/10.1016/j.eplepsyres.2022.107029.Kuyucu S., Caubet J.C. Hypersensitivity reactions to antiepileptic drugs in children: epidemiologic, pathogenetic, clinical, and diagnostic aspects. J Allergy Clin Immunol Pract. 2018; 6 (6): 1879–891.e1. https://doi.org/10.1016/j.jaip.2018.07.003.Kuyucu S., Caubet J.C. Hypersensitivity reactions to antiepileptic drugs in children: epidemiologic, pathogenetic, clinical, and diagnostic aspects. J Allergy Clin Immunol Pract. 2018; 6 (6): 1879–891.e1. https://doi.org/10.1016/j.jaip.2018.07.003.Zhao W., Meng H. Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population. Bioengineered. 2022; 13 (3): 7709–45. https://doi.org/10.1080/21655979.2022.2036916.Zhao W., Meng H. Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population. Bioengineered. 2022; 13 (3): 7709–45. https://doi.org/10.1080/21655979.2022.2036916.Галанкин Н.А., Тадтаева З.Г., Сардарян И.С. и др. Влияние генетических полиморфизмов CYP2C9, CYP2C19 и ABCB1 на безопасность и эффективность применения антиэпилептических препаратов. Эпилепсия и пароксизмальные состояния. 2025; 17 (1): 70–81. https://doi.org/10.17749/2077-8333/epi.par.con.2025.240.Galankin N.A., Tadtaeva Z.G., Sardaryan I.S., et al. Impact of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms on antiepileptic drug safety and efficacy. Epilepsia i paroksizmal'nye sostoania / Epilepsy and Paroxysmal Conditions. 2025; 17 (1): 70–81 (in Russ.). https://doi.org/10.17749/2077-8333/epi.par.con.2025.240.Li S., Cao J., Xiao N., Cai F. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy. J Child Neurol. 2010; 25 (5): 609–13. https://doi.org/10.1177/0883073809342489.Li S., Cao J., Xiao N., Cai F. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy. J Child Neurol. 2010; 25 (5): 609–13. https://doi.org/10.1177/0883073809342489.Incecik F., Hergüner M.O., Altunbasak S. The efficacy and side effects of levetiracetam on refractory epilepsy in children. J Pediatr Neurosci. 2012; 7 (1): 19–22. https://doi.org/10.4103/1817-1745.97614.Incecik F., Hergüner M.O., Altunbasak S. The efficacy and side effects of levetiracetam on refractory epilepsy in children. J Pediatr Neurosci. 2012; 7 (1): 19–22. https://doi.org/10.4103/1817-1745.97614.Zhao T., Yu J., Wang T.T., et al. Impact of ABCB1 polymorphism on levetiracetam serum concentrations in epileptic uygur children in china. Ther Drug Monit. 2020; 42 (6): 886–92. https://doi.org/10.1097/FTD.0000000000000805.Zhao T., Yu J., Wang T.T., et al. Impact of ABCB1 polymorphism on levetiracetam serum concentrations in epileptic uygur children in china. Ther Drug Monit. 2020; 42 (6): 886–92. https://doi.org/10.1097/FTD.0000000000000805.Тадтаева З.Г., Галустян А.Н., Громова О.А., Сардарян И.С. Антиэпилептические препараты третьего поколения: механизм действия, фармакокинетика, взаимодействие и применение в детском возрасте. Эпилепсия и пароксизмальные состояния. 2023; 15 (2): 160–70. https://doi.org/10.17749/2077-8333/epi.par.con.2023.149.Tadtaeva Z.G., Galustyan A.N., Gromova O.A., Sardaryan I.S. Third generation antiepileptic drugs: mechanism of action, pharmacokinetics, interaction and use in childhood. Epilepsia i paroksizmal'nye sostoania / Epilepsy and Paroxysmal Conditions. 2023; 15 (2): 160–70 (in Russ.). https://doi.org/10.17749/2077-8333/epi.par.con.2023.149.Карлов В.А. Эпилепсия у детей и взрослых женщин и мужчин. Руководство для врачей. 2-е изд. М.: Бином; 2019: 896 с.Karlov V.А. Epilepsy in children and adult women and men. A guide for doctors. 2nd ed. Мoscow: Binom; 2019: 896 pp. (in Russ.).Фомина М.Ю., Мелашенко Т.В. Эпилептические энцефалопатии и энцефалопатии развития младенческого возраста. Клинические наблюдения. Опыт Перинатального центра Санкт-Петербургского государственного педиатрического медицинского университета. Педиатр. 2025; 16 (2): 105–19. https://doi.org/10.56871/PED.2025.40.67.010.Fomina M.Yu., Melashenko T.V. Epileptic encephalopathies and developmental encephalopathies of infancy. Clinical observations. The experience of the Perinatal Center of St. Petersburg State Pediatric Medical University. Pediatrician (St. Petersburg). 2025; 16 (2): 105–19 (in Russ.). https://doi.org/10.56871/PED.2025.40.67.010.Farooq M.U., Bhatt A., Majid A., et al. Levetiracetam for managing neurologic and psychiatric disorders. Am J Health Syst Pharm. 2009; 66 (6): 541–61. https://doi.org/10.2146/ajhp070607.Farooq M.U., Bhatt A., Majid A., et al. Levetiracetam for managing neurologic and psychiatric disorders. Am J Health Syst Pharm. 2009; 66 (6): 541–61. https://doi.org/10.2146/ajhp070607.Карлов В.А., Кожокару А.Б., Власов П.Н. и др. Монотерапия леветирацетамом при впервые выявленной эпилепсии у взрослых с учетом индекса эпилептиформной активности. Эпилепсия и пароксизмальные состояния. 2020; 12 (2): 93–104. https://doi.org/10.17749/2077-8333/epi.par.con.2020.024.Karlov V.A., Kozhokaru A.B., Vlasov P.N., et al. Efficacy assessment of levetiracetam monotherapy in newly-diagnosed epilepsy in adults using epileptiform activity index. Epilepsia i paroksizmal'nye sostoania / Epilepsy and Paroxysmal Conditions. 2020; 12 (2): 93–104 (in Russ.) https://doi.org/10.17749/2077-8333/epi.par.con.2020.024.Cortes-Altamirano J.L., Olmos-Hernández A., Bonilla-Jaime H., et al. Levetiracetam as an antiepileptic, neuroprotective, and hyperalgesic drug. Neurol India. 2016; 64 (6): 1266–75. https://doi.org/10.4103/0028-3886.193801.Cortes-Altamirano J.L., Olmos-Hernández A., Bonilla-Jaime H., et al. Levetiracetam as an antiepileptic, neuroprotective, and hyperalgesic drug. Neurol India. 2016; 64 (6): 1266–75. https://doi.org/10.4103/0028-3886.193801.Pellock J.M., Glauser T.A., Bebin E.M., et al. Pharmacokinetic study of levetiracetam in children. Epilepsia. 2001; 42 (12): 1574–9. https://doi.org/10.1046/j.1528-1157.2001.41300.x.Pellock J.M., Glauser T.A., Bebin E.M., et al. Pharmacokinetic study of levetiracetam in children. Epilepsia. 2001; 42 (12): 1574–9. https://doi.org/10.1046/j.1528-1157.2001.41300.x.Baxter K. Stockley’s drug interactions: a source book of interactions, their mechanisms, clinical importance and management. 9th ed. Pharmaceutical Press; 2010: 1792 pp.Baxter K. Stockley’s drug interactions: a source book of interactions, their mechanisms, clinical importance and management. 9th ed. Pharmaceutical Press; 2010: 1792 pp.Mbizvo G.K., Dixon P., Hutton J.L., Marson A.G. The adverse effects profile of levetiracetam in epilepsy: a more detailed look. Int J Neurosci. 2014; 124 (9): 627–34. https://doi.org/10.3109/00207454.2013.866951.Mbizvo G.K., Dixon P., Hutton J.L., Marson A.G. The adverse effects profile of levetiracetam in epilepsy: a more detailed look. Int J Neurosci. 2014; 124 (9): 627–34. https://doi.org/10.3109/00207454.2013.866951.Wyllie E. (Ed.) Wyllie’s treatment of epilepsy: principles and practice. 7th ed. Lippincott Williams & Wilkins; 2021: 1096 pp.Wyllie E. (Ed.) Wyllie’s treatment of epilepsy: principles and practice. 7th ed. Lippincott Williams & Wilkins; 2021: 1096 pp.Howard P., Remi J., Remi C., et al. Levetiracetam. J Pain Symptom Manage. 2018; 56 (4): 645–9. https://doi.org/10.1016/j.jpainsymman.2018.07.012.Howard P., Remi J., Remi C., et al. Levetiracetam. J Pain Symptom Manage. 2018; 56 (4): 645–9. https://doi.org/10.1016/j.jpainsymman.2018.07.012.Hansen C.C., Ljung H., Brodtkorb E., Reimers A. Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel. Behav Neurol. 2018; 2018: 2064027. https://doi.org/10.1155/2018/2064027.Hansen C.C., Ljung H., Brodtkorb E., Reimers A. Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel. Behav Neurol. 2018; 2018: 2064027. https://doi.org/10.1155/2018/2064027.Mula M., Sander J.W. Suicidal ideation in epilepsy and levetiracetam therapy. Epilepsy Behav. 2007; 11 (1): 130–2. https://doi.org/10.1016/j.yebeh.2007.04.008.Mula M., Sander J.W. Suicidal ideation in epilepsy and levetiracetam therapy. Epilepsy Behav. 2007; 11 (1): 130–2. https://doi.org/10.1016/j.yebeh.2007.04.008.Esang M., Santos M.G., Ahmed S. Levetiracetam and suicidality: a case report and literature review. Prim Care Companion CNS Disord. 2020; 22 (4): 19nr02502. https://doi.org/10.4088/PCC.19nr02502.Esang M., Santos M.G., Ahmed S. Levetiracetam and suicidality: a case report and literature review. Prim Care Companion CNS Disord. 2020; 22 (4): 19nr02502. https://doi.org/10.4088/PCC.19nr02502.Tao K., Chen H., Chen Y., et al. Levetiracetam induces severe psychiatric symptoms in people with epilepsy. Seizure. 2024; 116: 147–50. https://doi.org/10.1016/j.seizure.2022.12.002.Tao K., Chen H., Chen Y., et al. Levetiracetam induces severe psychiatric symptoms in people with epilepsy. Seizure. 2024; 116: 147–50. https://doi.org/10.1016/j.seizure.2022.12.002.Erdogan S., Bosnak M. Hallucination: a rare complication of levetiracetam theraphy. North Clin Istanb. 2017; 4 (3): 267–9. https://doi.org/10.14744/nci.2017.44366.Erdogan S., Bosnak M. Hallucination: a rare complication of levetiracetam theraphy. North Clin Istanb. 2017; 4 (3): 267–9. https://doi.org/10.14744/nci.2017.44366.Shakya D.R., Dutta A., Gautam R. Hallucination in a seizure patient using levetiracetam: a case report. Case Report Med. 2012; 2012: 706243. https://doi.org/10.1155/2012/706243.Shakya D.R., Dutta A., Gautam R. Hallucination in a seizure patient using levetiracetam: a case report. Case Report Med. 2012; 2012: 706243. https://doi.org/10.1155/2012/706243.Tahir H., Ayyaz F., Ekwegh U. Visual and auditory hallucinations: an uncommon side effect of levetiracetam in an elderly patient. Cureus. 2022; 14 (10): e30668. https://doi.org/10.7759/cureus.30668.Tahir H., Ayyaz F., Ekwegh U. Visual and auditory hallucinations: an uncommon side effect of levetiracetam in an elderly patient. Cureus. 2022; 14 (10): e30668. https://doi.org/10.7759/cureus.30668.Camacho A., Espín J.C., Nuñez N., Simón R. Levetiracetam-induced reversible autistic regression. Pediatr Neurol. 2012; 47 (1): 65–7. https://doi.org/10.1016/j.pediatrneurol.2012.04.002.Camacho A., Espín J.C., Nuñez N., Simón R. Levetiracetam-induced reversible autistic regression. Pediatr Neurol. 2012; 47 (1): 65–7. https://doi.org/10.1016/j.pediatrneurol.2012.04.002.Zhou D.J., Pavuluri S., Snehal I., et al. Movement disorders associated with antiseizure medications: a systematic review. Epilepsy Behav. 2022; 131 (Pt A): 108693. https://doi.org/10.1016/j.yebeh.2022.108693.Zhou D.J., Pavuluri S., Snehal I., et al. Movement disorders associated with antiseizure medications: a systematic review. Epilepsy Behav. 2022; 131 (Pt A): 108693. https://doi.org/10.1016/j.yebeh.2022.108693.Yim S.H., Choi Y.H., Heo K., Cho K.H. A case of dyskinesia after levetiracetam administration. BMC Neurol. 2019; 19 (1): 292. https://doi.org/10.1186/s12883-019-1519-8.Yim S.H., Choi Y.H., Heo K., Cho K.H. A case of dyskinesia after levetiracetam administration. BMC Neurol. 2019; 19 (1): 292. https://doi.org/10.1186/s12883-019-1519-8.Le V., Surineni K., Elias G. A case of partially reversible oral-buccal-lingual dyskinesia after prolonged levetiracetam exposure. Am J Geriatr Psychiatry. 2024; 32 (4): S106. https://doi.org/10.1016/j.jagp.2024.01.190.Le V., Surineni K., Elias G. A case of partially reversible oral-buccal-lingual dyskinesia after prolonged levetiracetam exposure. Am J Geriatr Psychiatry. 2024; 32 (4): S106. https://doi.org/10.1016/j.jagp.2024.01.190.Lee J.S., Woo H.G., Hwang K.J. Tongue tremor after levetiracetam administration. J Clin Neurol. 2021; 17 (4): 588–9. https://doi.org/10.3988/jcn.2021.17.4.588.Lee J.S., Woo H.G., Hwang K.J. Tongue tremor after levetiracetam administration. J Clin Neurol. 2021; 17 (4): 588–9. https://doi.org/10.3988/jcn.2021.17.4.588.Surineni K., Le V., Jones D. A case of oral-buccal-lingual dyskinesia and neuropsychiatric symptoms after prolonged levetiracetam exposure. Cureus. 2024; 16 (6): e62692. https://doi.org/10.7759/cureus.62692.Surineni K., Le V., Jones D. A case of oral-buccal-lingual dyskinesia and neuropsychiatric symptoms after prolonged levetiracetam exposure. Cureus. 2024; 16 (6): e62692. https://doi.org/10.7759/cureus.62692.Badarny S., Badarny Y., Mihilia F. Republished: Unusual side effects of levetiracetam. Drug Ther Bull. 2023; 61 (2): 30–1. https://doi.org/10.1136/dtb.2022.242496rep.Badarny S., Badarny Y., Mihilia F. Republished: Unusual side effects of levetiracetam. Drug Ther Bull. 2023; 61 (2): 30–1. https://doi.org/10.1136/dtb.2022.242496rep.Falhammar H., Lindh J.D., Calissendorff J., et al. Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: a population-based case-control study. Seizure. 2018; 59: 28–33. https://doi.org/10.1016/j.seizure.2018.04.025.Falhammar H., Lindh J.D., Calissendorff J., et al. Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: a population-based case-control study. Seizure. 2018; 59: 28–33. https://doi.org/10.1016/j.seizure.2018.04.025.Nasrallah K., Silver B. Hyponatremia associated with repeated use of levetiracetam. Epilepsia. 2005; 46 (6): 972–3. https://doi.org/10.1111/j.1528-1167.2005.64004.x.Nasrallah K., Silver B. Hyponatremia associated with repeated use of levetiracetam. Epilepsia. 2005; 46 (6): 972–3. https://doi.org/10.1111/j.1528-1167.2005.64004.x.Rosca E.C., Simu M. Levetiracetam-induced hyponatremia. Acta Neurol Belg. 2018; 118 (1): 123–4. https://doi.org/10.1007/s13760-017-0825-4.Rosca E.C., Simu M. Levetiracetam-induced hyponatremia. Acta Neurol Belg. 2018; 118 (1): 123–4. https://doi.org/10.1007/s13760-017-0825-4.Belcastro V., Costa C., Striano P. Levetiracetam-associated hyponatremia. Seizure. 2008; 17 (4): 389–90. https://doi.org/10.1016/j.seizure.2007.10.007.Belcastro V., Costa C., Striano P. Levetiracetam-associated hyponatremia. Seizure. 2008; 17 (4): 389–90. https://doi.org/10.1016/j.seizure.2007.10.007.Nägele H., Rosenkranz M., Nägele M.P. Hyponatremia-induced epileptic seizure provoked by levetiracetam and pain medication intake in a patient with central diabetes insipidus. Case Rep Neurol. 2024; 16 (1): 204–7. https://doi.org/10.1159/000540320.Nägele H., Rosenkranz M., Nägele M.P. Hyponatremia-induced epileptic seizure provoked by levetiracetam and pain medication intake in a patient with central diabetes insipidus. Case Rep Neurol. 2024; 16 (1): 204–7. https://doi.org/10.1159/000540320.Gattu A.K., Murthy J.M.K. Recurrent hyponatremia: levetiracetam – an uncommon cause. Ann Indian Acad Neurol. 2023; 26 (3): 302–4. https://doi.org/10.4103/aian.aian_996_22.Gattu A.K., Murthy J.M.K. Recurrent hyponatremia: levetiracetam – an uncommon cause. Ann Indian Acad Neurol. 2023; 26 (3): 302–4. https://doi.org/10.4103/aian.aian_996_22.Coughlin P., Patel G., Vadaketh J., Pandit R. A rare case of levetiracetam-induced refractory hypokalemia. Cureus. 2022; 14 (4): e23817. https://doi.org/10.7759/cureus.23817.Coughlin P., Patel G., Vadaketh J., Pandit R. A rare case of levetiracetam-induced refractory hypokalemia. Cureus. 2022; 14 (4): e23817. https://doi.org/10.7759/cureus.23817.Aksoy D., Cevik B., Kurt S., et al. Hypokalemia and hypomagnesaemia related to levetiracetam use. J Clin Neurosci. 2014; 21 (11): 1989–90. https://doi.org/10.1016/j.jocn.2014.03.013.Aksoy D., Cevik B., Kurt S., et al. Hypokalemia and hypomagnesaemia related to levetiracetam use. J Clin Neurosci. 2014; 21 (11): 1989–90. https://doi.org/10.1016/j.jocn.2014.03.013.Vallianou N.G., Geladari E., Chroni P., Kokkinakis E. Levetiracetam-associated hypokalemia and hypomagnesaemia among two patients treated for seizures. CNS Neurosci Ther. 2015; 21 (6): 539. https://doi.org/10.1111/cns.12398.Vallianou N.G., Geladari E., Chroni P., Kokkinakis E. Levetiracetam-associated hypokalemia and hypomagnesaemia among two patients treated for seizures. CNS Neurosci Ther. 2015; 21 (6): 539. https://doi.org/10.1111/cns.12398.Ammad Ud Din M., Ather Hussain S., Bodrog A. delayed recognition of levetiracetam-induced pancytopenia. Eur J Case Rep Intern Med. 2021; 8 (3): 002449. https://doi.org/10.12890/2021_002449.Ammad Ud Din M., Ather Hussain S., Bodrog A. delayed recognition of levetiracetam-induced pancytopenia. Eur J Case Rep Intern Med. 2021; 8 (3): 002449. https://doi.org/10.12890/2021_002449.Unkun R., Kizilkilic E.K., Delil S., et al. Levetiracetam-associated pancytopenia. Acta Neurol Belg. 2023; 123 (4): 1625–6. https://doi.org/10.1007/s13760-022-02138-1.Unkun R., Kizilkilic E.K., Delil S., et al. Levetiracetam-associated pancytopenia. Acta Neurol Belg. 2023; 123 (4): 1625–6. https://doi.org/10.1007/s13760-022-02138-1.Jain R.S., Srivastava T., Sharma P., Pemawat A. Levetiracetam-mediated drug-induced liver injury – a rare presentation and review of literature. Ann Indian Acad Neurol. 2024; 27 (1): 87–90. https://doi.org/10.4103/aian.aian_730_23.Jain R.S., Srivastava T., Sharma P., Pemawat A. Levetiracetam-mediated drug-induced liver injury – a rare presentation and review of literature. Ann Indian Acad Neurol. 2024; 27 (1): 87–90. https://doi.org/10.4103/aian.aian_730_23.Moinuddin I.A. Suspected levetiracetam-induced rhabdomyolysis: a case report and literature review. Am J Case Rep. 2020; 21: e926064. https://doi.org/10.12659/AJCR.926064.Moinuddin I.A. Suspected levetiracetam-induced rhabdomyolysis: a case report and literature review. Am J Case Rep. 2020; 21: e926064. https://doi.org/10.12659/AJCR.926064.Lyles S., Atalay R.T., Taylor S., et al. Weighing the risk of seizure control: a case of levetiracetam-induced rhabdomyolysis. Cureus. 2024; 16 (11): e74111. https://doi.org/10.7759/cureus.74111.Lyles S., Atalay R.T., Taylor S., et al. Weighing the risk of seizure control: a case of levetiracetam-induced rhabdomyolysis. Cureus. 2024; 16 (11): e74111. https://doi.org/10.7759/cureus.74111.Kodama K., Imai T., Kuwana T., et al. Two cases of levetiracetam-induced rhabdomyolysis with low levetiracetam blood concentrations. Cureus. 2025; 17 (3): e80877. https://doi.org/10.7759/cureus.80877.Kodama K., Imai T., Kuwana T., et al. Two cases of levetiracetam-induced rhabdomyolysis with low levetiracetam blood concentrations. Cureus. 2025; 17 (3): e80877. https://doi.org/10.7759/cureus.80877.Kazmi J.S., Albarghouthy N., Ramsaywak R. Levetiracetam-induced rhabdomyolysis reversed by discontinuation: a case report. Cureus. 2023; 15 (11): e48955. https://doi.org/10.7759/cureus.48955.Kazmi J.S., Albarghouthy N., Ramsaywak R. Levetiracetam-induced rhabdomyolysis reversed by discontinuation: a case report. Cureus. 2023; 15 (11): e48955. https://doi.org/10.7759/cureus.48955.Romero K.N., O’Brien M.C., Agrawal A., Hasan I. Creatine kinase surge: levetiracetam-induced rhabdomyolysis. Cureus. 2024; 16 (8): e66715. https://doi.org/10.7759/cureus.66715.Romero K.N., O’Brien M.C., Agrawal A., Hasan I. Creatine kinase surge: levetiracetam-induced rhabdomyolysis. Cureus. 2024; 16 (8): e66715. https://doi.org/10.7759/cureus.66715.Qureshi M., Abraham P.A., Al-Faras A., et al. Rhabdomyolysis induced by levetiracetam: a case report in kuwait. Case Rep Neurol Med. 2024; 2024: 1234738. https://doi.org/10.1155/2024/1234738.Qureshi M., Abraham P.A., Al-Faras A., et al. Rhabdomyolysis induced by levetiracetam: a case report in kuwait. Case Rep Neurol Med. 2024; 2024: 1234738. https://doi.org/10.1155/2024/1234738.Algahtani H., Marghalani S., Satti M., Shirah B. Levetiracetam-induced skin hyperpigmentation: an extremely rare undesirable side effect. J Epilepsy Res. 2017; 7 (2): 106–8. https://doi.org/10.14581/jer.17016.Algahtani H., Marghalani S., Satti M., Shirah B. Levetiracetam-induced skin hyperpigmentation: an extremely rare undesirable side effect. J Epilepsy Res. 2017; 7 (2): 106–8. https://doi.org/10.14581/jer.17016.Rashid M., Rajan A.K., Chhabra M., Kashyap A. Levetiracetam and cutaneous adverse reactions: a systematic review of descriptive studies. Seizure. 2020; 75: 101–9. https://doi.org/10.1016/j.seizure.2020.01.002.Rashid M., Rajan A.K., Chhabra M., Kashyap A. Levetiracetam and cutaneous adverse reactions: a systematic review of descriptive studies. Seizure. 2020; 75: 101–9. https://doi.org/10.1016/j.seizure.2020.01.002.Lim J.A., Jamil A., Ramli N.A., et al. Severe cutaneous adverse reaction to drug excipient following brand-to-generic switch of levetiracetam. Am J Health Syst Pharm. 2024; 81 (3): e69–72. https://doi.org/10.1093/ajhp/zxad264.Lim J.A., Jamil A., Ramli N.A., et al. Severe cutaneous adverse reaction to drug excipient following brand-to-generic switch of levetiracetam. Am J Health Syst Pharm. 2024; 81 (3): e69–72. https://doi.org/10.1093/ajhp/zxad264.Kahraman Ş., Değermenci Ş., Oktay M.A., et al. Anaphylaxis to levetiracetam in an adolescent: a very rare occurence. Turk J Pediatr. 2021; 63 (3): 506–9. https://doi.org/10.24953/turkjped.2021.03.019.Kahraman Ş., Değermenci Ş., Oktay M.A., et al. Anaphylaxis to levetiracetam in an adolescent: a very rare occurence. Turk J Pediatr. 2021; 63 (3): 506–9. https://doi.org/10.24953/turkjped.2021.03.019.Alkhotani A., McLachlan R.S. Levetiracetam induced angioedema in a patient with previous anticonvulsant hypersensitivity reaction to phenytoin and lamotrigine. Seizure. 2012; 21 (5): 407–8. https://doi.org/10.1016/j.seizure.2012.03.007.Alkhotani A., McLachlan R.S. Levetiracetam induced angioedema in a patient with previous anticonvulsant hypersensitivity reaction to phenytoin and lamotrigine. Seizure. 2012; 21 (5): 407–8. https://doi.org/10.1016/j.seizure.2012.03.007.Koklu E., Ariguloglu E.A., Koklu S. Levetiracetam-induced anaphylaxis in a neonate. Pediatr Neurol. 2014; 50 (2): 192–4. https://doi.org/10.1016/j.pediatrneurol.2013.09.006.Koklu E., Ariguloglu E.A., Koklu S. Levetiracetam-induced anaphylaxis in a neonate. Pediatr Neurol. 2014; 50 (2): 192–4. https://doi.org/10.1016/j.pediatrneurol.2013.09.006.Callenbach P.M.C., Arts W.F.M., ten Houten R., et al. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study. Eur J Paediatr Neurol. 2008; 12 (4): 321–7. https://doi.org/10.1016/j.ejpn.2007.09.004.Callenbach P.M.C., Arts W.F.M., ten Houten R., et al. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study. Eur J Paediatr Neurol. 2008; 12 (4): 321–7. https://doi.org/10.1016/j.ejpn.2007.09.004.Delanty N., Jones J., Tonner F. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. Epilepsia. 2012; 53 (1): 111–9. https://doi.org/10.1111/j.1528-1167.2011.03300.x.Delanty N., Jones J., Tonner F. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. Epilepsia. 2012; 53 (1): 111–9. https://doi.org/10.1111/j.1528-1167.2011.03300.x.Mula M., Trimble M.R., Sander J.W.A.S. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure. 2004; 13 (1): 55–7. https://doi.org/10.1016/S1059-1311(03)00111-0.Mula M., Trimble M.R., Sander J.W.A.S. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure. 2004; 13 (1): 55–7. https://doi.org/10.1016/S1059-1311(03)00111-0.White J.R., Walczak T.S., Leppik I.E., et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology. 2003; 61 (9): 1218–21. https://doi.org/10.1212/01.wnl.0000091865.46063.67.White J.R., Walczak T.S., Leppik I.E., et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology. 2003; 61 (9): 1218–21. https://doi.org/10.1212/01.wnl.0000091865.46063.67.Helmstaedter C., Mihov Y., Toliat M.R., et al. Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. Epilepsia. 2013; 54 (1): 36–44. https://doi.org/10.1111/j.1528-1167.2012.03603.x.Helmstaedter C., Mihov Y., Toliat M.R., et al. Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. Epilepsia. 2013; 54 (1): 36–44. https://doi.org/10.1111/j.1528-1167.2012.03603.x.Campbell C., McCormack M., Patel S., et al. A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam. Epilepsia. 2022; 63 (6): 1563–70. https://doi.org/10.1111/epi.17228.Campbell C., McCormack M., Patel S., et al. A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam. Epilepsia. 2022; 63 (6): 1563–70. https://doi.org/10.1111/epi.17228.Doumiati H., Ezzeddine A. Dyskinesia after levetiracetam therapy: a case report. Res Sq. Published online May 7, 2024. https://doi.org/10.21203/rs.3.rs-4343478/v1.Doumiati H., Ezzeddine A. Dyskinesia after levetiracetam therapy: a case report. Res Sq. Published online May 7, 2024. https://doi.org/10.21203/rs.3.rs-4343478/v1.Зыков В.П., Каширина Э.А., Наугольных Ю.В. Новые возможности терапии тикозных гиперкинезов с использованием препаратов антиконвульсантного ряда. Эпилепсия и пароксизмальные состояния. 2016; 8 (3): 45–51. https://doi.org/10.17749/2077-8333.2016.8.3.045-051.Zykov V.P., Kashirina E.A., Naugolnykh Yu.V. Possibilities of tic hyperkinesia therapy using antiсonvulsants. Epilepsia i paroksizmal'nye sostoania / Epilepsy and Paroxysmal Conditions. 2016; 8 (3): 45–51 (in Russ.). https://doi.org/10.17749/2077-8333.2016.8.3.045-051.Vles G.F., Hendriksen J.G., Visschers A., et al. Levetiracetam therapy for treatment of choreoathetosis in dyskinetic cerebral palsy. Dev Med Child Neurol. 2009; 51 (6): 487–90. https://doi.org/10.1111/j.1469-8749.2008.03170.x.Vles G.F., Hendriksen J.G., Visschers A., et al. Levetiracetam therapy for treatment of choreoathetosis in dyskinetic cerebral palsy. Dev Med Child Neurol. 2009; 51 (6): 487–90. https://doi.org/10.1111/j.1469-8749.2008.03170.x.Lu X., Wang X. Hyponatremia induced by antiepileptic drugs in patients with epilepsy. Expert Opin Drug Saf. 2017; 16 (1): 77–87. https://doi.org/10.1080/14740338.2017.1248399.Lu X., Wang X. Hyponatremia induced by antiepileptic drugs in patients with epilepsy. Expert Opin Drug Saf. 2017; 16 (1): 77–87. https://doi.org/10.1080/14740338.2017.1248399.Durá-Travé T., Gallinas-Victoriano F., Malumbres-Chacón M., et al. Vitamin D deficiency in children with epilepsy taking valproate and levetiracetam as monotherapy. Epilepsy Res. 2018; 139: 80–4. https://doi.org/10.1016/j.eplepsyres.2017.11.013.Durá-Travé T., Gallinas-Victoriano F., Malumbres-Chacón M., et al. Vitamin D deficiency in children with epilepsy taking valproate and levetiracetam as monotherapy. Epilepsy Res. 2018; 139: 80–4. https://doi.org/10.1016/j.eplepsyres.2017.11.013.Maher Zidan A., Abd El Azim Abd El Aziz S., Ahmed El-Serogy H., Mohammed El-Sawy D. Effects of levetiracetam monotherapy on vitamin D status and serum calcium in children with epilepsy. Asian J Pediatr Res. Published online February 6, 2023. https://doi.org/10.9734/ajpr/2023/v11i1212.Maher Zidan A., Abd El Azim Abd El Aziz S., Ahmed El-Serogy H., Mohammed El-Sawy D. Effects of levetiracetam monotherapy on vitamin D status and serum calcium in children with epilepsy. Asian J Pediatr Res. Published online February 6, 2023. https://doi.org/10.9734/ajpr/2023/v11i1212.Jiang X., Xiong F., Wu S., et al. Effects of levetiracetam on bone mineral density and bone metabolism in patients with epilepsy: a systematic review and meta-analysis. Epilepsy Behav. 2024; 158: 109925. https://doi.org/10.1016/j.yebeh.2024.109925.Jiang X., Xiong F., Wu S., et al. Effects of levetiracetam on bone mineral density and bone metabolism in patients with epilepsy: a systematic review and meta-analysis. Epilepsy Behav. 2024; 158: 109925. https://doi.org/10.1016/j.yebeh.2024.109925.Aksoy D., Güveli B.T., Ak P.D., et al. Effects of oxcarbazepine and levetiracetam on calcium, ionized calcium, and 25-OH vitamin-D3 levels in patients with epilepsy. Clin Psychopharmacol Neurosci. 2016; 14 (1): 74–8. https://doi.org/10.9758/cpn.2016.14.1.74.Aksoy D., Güveli B.T., Ak P.D., et al. Effects of oxcarbazepine and levetiracetam on calcium, ionized calcium, and 25-OH vitamin-D3 levels in patients with epilepsy. Clin Psychopharmacol Neurosci. 2016; 14 (1): 74–8. https://doi.org/10.9758/cpn.2016.14.1.74.Attilakos A., Tsirouda M., Dinopoulos A., et al. Vitamin D status in children with epilepsy treated with levetiracetam monotherapy. Epilepsy Res. 2018; 148: 116. https://doi.org/10.1016/j.eplepsyres.2018.09.003.Attilakos A., Tsirouda M., Dinopoulos A., et al. Vitamin D status in children with epilepsy treated with levetiracetam monotherapy. Epilepsy Res. 2018; 148: 116. https://doi.org/10.1016/j.eplepsyres.2018.09.003.Saket S., Varasteh N., Halimi Asl A.A., Saneifard H. How antiepileptics may change the serum level of vitamin D, calcium, and phosphorus in children with epilepsy. Iran J Child Neurol. 2021; 15 (1): 19–27. https://doi.org/10.22037/ijcn.v15i1.25952.Saket S., Varasteh N., Halimi Asl A.A., Saneifard H. How antiepileptics may change the serum level of vitamin D, calcium, and phosphorus in children with epilepsy. Iran J Child Neurol. 2021; 15 (1): 19–27. https://doi.org/10.22037/ijcn.v15i1.25952.Sahaya K., Goyal M.K., Sarwal A., Singh N.N. Levetiracetam-induced thrombocytopenia among inpatients: a retrospective study. Epilepsia. 2010; 51 (12): 2492–5. https://doi.org/10.1111/j.1528-1167.2010.02788.x.Sahaya K., Goyal M.K., Sarwal A., Singh N.N. Levetiracetam-induced thrombocytopenia among inpatients: a retrospective study. Epilepsia. 2010; 51 (12): 2492–5. https://doi.org/10.1111/j.1528-1167.2010.02788.x.Ucar H.K., Sarigecili E., Bilen S., Sari S. Short-term and long-term effects of levetiracetam monotherapy on hematological parameters in children with idiopathic epilepsy. Sisli Etfal Hastan Tip Bul. 2023; 57 (1): 46–53. https://doi.org/10.14744/SEMB.2022.98523.Ucar H.K., Sarigecili E., Bilen S., Sari S. Short-term and long-term effects of levetiracetam monotherapy on hematological parameters in children with idiopathic epilepsy. Sisli Etfal Hastan Tip Bul. 2023; 57 (1): 46–53. https://doi.org/10.14744/SEMB.2022.98523.Vidaurre J., Gedela S., Yarosz S. Antiepileptic drugs and liver disease. Pediatr Neurol. 2017; 77: 23–36. https://doi.org/10.1016/j.pediatrneurol.2017.09.013.Vidaurre J., Gedela S., Yarosz S. Antiepileptic drugs and liver disease. Pediatr Neurol. 2017; 77: 23–36. https://doi.org/10.1016/j.pediatrneurol.2017.09.013.Tan T.C.H., de Boer B.W., Mitchell A., et al. Levetiracetam as a possible cause of fulminant liver failure. Neurology. 2008; 71 (9): 685–6. https://doi.org/10.1212/01.wnl.0000324604.11657.c6.Tan T.C.H., de Boer B.W., Mitchell A., et al. Levetiracetam as a possible cause of fulminant liver failure. Neurology. 2008; 71 (9): 685–6. https://doi.org/10.1212/01.wnl.0000324604.11657.c6.Rogalewski A., Zuhorn F., Wilkens L., et al. Severe drug-induced liver injury caused by levetiracetam – a case report and review of the literature. Epilepsy Behav Rep. 2021; 16: 100464. https://doi.org/10.1016/j.ebr.2021.100464.Rogalewski A., Zuhorn F., Wilkens L., et al. Severe drug-induced liver injury caused by levetiracetam – a case report and review of the literature. Epilepsy Behav Rep. 2021; 16: 100464. https://doi.org/10.1016/j.ebr.2021.100464.Kashiura M., Sugiyama K., Hamabe Y. Association between rapid serum sodium correction and rhabdomyolysis in water intoxication: a retrospective cohort study. J Intensive Care. 2017; 5: 37. https://doi.org/10.1186/s40560-017-0233-0.Kashiura M., Sugiyama K., Hamabe Y. Association between rapid serum sodium correction and rhabdomyolysis in water intoxication: a retrospective cohort study. J Intensive Care. 2017; 5: 37. https://doi.org/10.1186/s40560-017-0233-0.Rastogi V., Singh D., Kaur B., et al. Rhabdomyolysis: a rare adverse effect of levetiracetam. Cureus. 2018; 10 (5): e2705. https://doi.org/10.7759/cureus.2705.Rastogi V., Singh D., Kaur B., et al. Rhabdomyolysis: a rare adverse effect of levetiracetam. Cureus. 2018; 10 (5): e2705. https://doi.org/10.7759/cureus.2705.Jones R.T., Evans W., Mersfelder TL., Kavanaugh K. Rare red rashes: a case report of levetiracetam-induced cutaneous reaction and review of the literature. Am J Ther. 2016; 23 (3): e944–6. https://doi.org/10.1097/MJT.0000000000000105.Jones R.T., Evans W., Mersfelder TL., Kavanaugh K. Rare red rashes: a case report of levetiracetam-induced cutaneous reaction and review of the literature. Am J Ther. 2016; 23 (3): e944–6. https://doi.org/10.1097/MJT.0000000000000105.Kim H.K., Kim D.Y., Bae E.K., Kim D.W. Adverse skin reactions with antiepileptic drugs using Korea adverse event reporting system database, 2008–2017. J Korean Med Sci. 2020; 35 (4): e17. https://doi.org/10.3346/jkms.2020.35.e17.Kim H.K., Kim D.Y., Bae E.K., Kim D.W. Adverse skin reactions with antiepileptic drugs using Korea adverse event reporting system database, 2008–2017. J Korean Med Sci. 2020; 35 (4): e17. https://doi.org/10.3346/jkms.2020.35.e17.Мелашенко Т.В., Пальчик А.Б. Фетальный вальпроатный синдром (обзор литературы и описание клинического случая). Педиатр. 2023; 14 (2): 117–25. https://doi.org/10.17816/PED14-2-117-125.Melashenko T.V., Palchik A.B. Fetal valproate syndrome (review and case report). Pediatrician (St. Petersburg). 2023; 14 (2): 117–25. https://doi.org/10.17816/PED142117-125.Tural S., Tekcan A., Elbistan M., et al. Genotoxic effects of prenatal exposure to levetiracetam during pregnancy on rat offsprings. In Vivo. 2015; 29 (1): 77–81.Tural S., Tekcan A., Elbistan M., et al. Genotoxic effects of prenatal exposure to levetiracetam during pregnancy on rat offsprings. In Vivo. 2015; 29 (1): 77–81.French J., Edrich P., Cramer J.A. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res. 2001; 47 (1-2): 77–90. https://doi.org/10.1016/s0920-1211(01)00296-0.French J., Edrich P., Cramer J.A. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res. 2001; 47 (1-2): 77–90. https://doi.org/10.1016/s0920-1211(01)00296-0.He Z., Liu C., Lin L., et al. Real-world safety of levetiracetam: mining and analysis of its adverse drug reactions based on FAERS database. Seizure. 2024; 117: 253–60. https://doi.org/10.1016/j.seizure.2024.03.009.He Z., Liu C., Lin L., et al. Real-world safety of levetiracetam: mining and analysis of its adverse drug reactions based on FAERS database. Seizure. 2024; 117: 253–60. https://doi.org/10.1016/j.seizure.2024.03.009.

The authors declare that there are no conflicts of interest present.